The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesCharacterization of leukemias and lymphomas in human lysed whole peripheral blood or mononuclear cells separated by density gradient.
CD19 (FITC) immunofluorescence analysis can be performed on a flow cytometerequipped with an excitation source of 488nm and fitted with logarithmic amplifiers.
10µl ofCD19 (FITC) is sufficient for labelling of 1x106 cells.
FunctionAssembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Involvement in diseaseDefects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
Antibody deficiency due to defect in CD19, included antibody
B lymphocyte antigen CD19 antibody
B lymphocyte surface antigen B4 antibody
B-lymphocyte antigen CD19 antibody
B-lymphocyte surface antigen B4 antibody
CD19 antigen antibody
CD19 molecule antibody
Cd19 protein antibody
Differentiation antigen CD19 antibody
Leu 12 antibody
T-cell surface antigen Leu-12 antibody
References for Anti-CD19 antibody [CB19] (FITC) (ab1167)
This product has been referenced in:
Bradbury LE et al. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol149:2841-50 (1992).
Read more (PubMed: 1383329) »
Carter RH & Fearon DT CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science256:105-7 (1992).
Read more (PubMed: 1373518) »